INTRODUCTION: Brentuximab vedotin (SGN-35), an @entity2686 ( @entity2686 )-30 antibody conjugated to the anti-tubulin agent @entity17335 , has demonstrated promising efficacy and tolerability in relapsed and heavily treated @entity978 ( @entity978 ). In this study, we report the Asian experience with brentuximab vedotin in @entity1 with relapsed or refractory @entity5823 -positive ( @entity5823 +) @entity978 . METHODS: This is an observational, multicenter, retrospective study. Between October 2011 and June 2013, a total of 22 @entity1 were treated with brentuximab vedotin under a named @entity1 program in Asia. @entity1 received a 30 min infusion of brentuximab vedotin at a dose of 1.8 mg/kg of body weight every 3 weeks. RESULTS: Four @entity1 (18.2%) showed a complete response, and the overall response rate was 72.7%. The median duration of response was 4.4 months (range 1.0-17.4). The median progression-free survival was 5.7 months, and the median overall survival has not yet been reached. The 1-year expected survival rate was 67.2%. The most common grade 3/4 adverse events were @entity1398 (n=7; 31.8%). No @entity1 experienced grade 3/4 @entity16 . CONCLUSIONS: These results confirm that brentuximab vedotin as a single agent is also effective and well tolerated when used in Asian @entity1 with relapsed and refractory @entity5823 + @entity978 .

Brentuximab vedotin for relapsed or refractory XXXX + @entity978 : a multicenter analysis from Asia.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity16 :: ('MESH:D009422', 'Disease') :: ['sensory neuropathy'] @entity2686 :: ('MESH:D003027', 'Disease') :: ['anti-cluster of differentiation', 'CD'] @entity17335 :: ('MESH:C495575', 'Chemical') :: ['monomethyl auristatin E'] @entity5823 :: ('943', 'Gene') :: ['CD30'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma']
@entity5823 :: (943,Gene) :: ['CD30']
